Document is current
Any future updates will be listed below
-
Authors
Abou Haidar, Edwina https://orcid.org/0000-0002-7866-8030
Prabhakar, Shilpa https://orcid.org/0000-0002-7999-2000
Cheah, Pike See
Hanlon, Killian S.
Espinoza, Paula
Crain, Adam V.
Patel, Nikita
Radcliff, Greta W.
Cheng, Ming
Hernández, Iván Coto
Minderler, Steven
de la Cruz, Demitri
Ng, Carrie
da Hora, Cintia Carla
Charest, Alain
Stemmer-Rachamimov, Anat
Jowett, Nate https://orcid.org/0000-0002-5242-0264
Breakefield, Xandra O. https://orcid.org/0000-0001-6036-0399
Maguire, Casey A. https://orcid.org/0000-0001-8681-5179
- License Information
-
More Information
Article History
Received: 30 April 2024
Revised: 15 May 2025
Accepted: 23 May 2025
First Online: 10 June 2025
Competing interests
: CAM has a financial interest in Sphere Gene Therapeutics, Inc., Chameleon Biosciences, Inc., and Skylark Bio, Inc., companies developing gene therapy platforms. CAM’s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict-of-interest policies.
: All animal procedures were performed in accordance with Massachusetts General Hospital’s (MGH’s) recommendations for the care and use of animals and were maintained and handled under protocols approved by the Institutional Animal Care and Use Committee (IACUC).
